Innovent Reports Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Meets Primary Endpoint for Inactive Thyroid Eye Disease

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED)